ResMed's GLP-1 Shadow Meets Margin Expansion Nobody Expected

ResMed Inc. (RMD) reports fiscal Q4 2026 earnings tomorrow, August 6, after market close, with analysts expecting $2.90 per share on revenue of approximately $1.47 billion. The medical device maker faces a critical test as investors assess whether its momentum in sleep apnea and respiratory care can sustain double-digit growth rates amid rising profitability expectations. With the stock trading near $224 and analyst sentiment recently deteriorating, the report will determine whether ResMed can justify its premium valuation.

Part 1: Earnings Preview

ResMed Inc. develops, manufactures, and distributes medical devices for treating sleep-disordered breathing and other respiratory conditions, with its core business focused on continuous positive airway pressure (CPAP) devices, masks, and cloud-connected digital health platforms. The company serves patients across sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory markets globally.

ResMed reports fiscal Q4 2026 results tomorrow, August 6, after market close. Analysts expect earnings of $2.90 per share on revenue of approximately $1.47 billion, representing 13.73% year-over-year EPS growth compared to $2.55 reported in the same quarter last year. The most recently reported quarter (Q3 2026, ending March 31) delivered $2.86 per share, beating estimates and marking the fourth consecutive quarterly beat.

Three key themes define this earnings story:

Margin Expansion Trajectory: ResMed's gross margin reached 62.8% in Q3—a 290 basis point year-over-year improvement—while operating margin expanded 230 basis points to 36.7%. Investors will scrutinize whether the company can sustain its FY2026 gross margin guidance of 62-63% and continue leveraging cost efficiencies and favorable product mix into the fiscal year-end.

Masks and Accessories Growth Engine: The masks and accessories segment drove 12% global sales growth in Q3, outpacing device sales and demonstrating the recurring revenue power of ResMed's consumables business. Continued strength here would validate the company's strategy of building a sticky, high-margin installed base.

Competitive Positioning in Sleep Apnea Market: With rival Philips still recovering from its CPAP recall issues, ResMed has captured significant market share. The question is whether this tailwind remains durable or if competitive pressures are beginning to normalize, potentially constraining future growth rates.

Analysts have grown more cautious heading into the print. The consensus recommendation has weakened from 3.85 one month ago to 3.70 currently, with one analyst downgrading from Buy to Hold. However, the $238.57 average price target still implies modest upside, and eight analysts maintain Strong Buy ratings, suggesting confidence in the long-term growth story despite near-term valuation concerns.

Part 2: Historical Earnings Performance

ResMed has established a consistent pattern of exceeding analyst expectations, beating EPS estimates in each of the past four quarters. The beats have been meaningful but not dramatic, ranging from 2.41% to 4.46%, with an average surprise of approximately 3.26%. This steady outperformance suggests conservative analyst modeling or genuine operational momentum—likely both.

The trend shows accelerating earnings power: reported EPS climbed from $2.55 in both Q4 and Q1 FY2026 to $2.81 in Q2 and $2.86 in Q3, reflecting sequential improvement even as year-over-year comparisons remained strong. The company has demonstrated the ability to translate revenue growth into expanding profitability, with each quarter's beat accompanied by margin expansion commentary.

Given this track record, investors will likely expect another beat tomorrow. However, the magnitude of recent surprises has been relatively modest compared to the stock's historical volatility around earnings, suggesting the market may already be pricing in some degree of outperformance. The real question is whether ResMed can deliver a beat large enough—or guidance strong enough—to justify further multiple expansion from current levels.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

ResMed typically reports after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

ResMed's post-earnings price behavior shows significant volatility, with an average absolute Day +1 move of 4.87%—well above typical daily trading ranges. The direction has been mixed: three of the past eight reports triggered declines (including a sharp -8.33% drop in January 2025 and -4.11% in April 2026), while five produced gains (notably +10.10% in April 2025 and +7.12% in October 2024).

The Day 0 moves average just 0.85%, indicating limited anticipatory positioning, but Day 0 trading ranges average 2.90%, suggesting heightened intraday volatility as traders position ahead of the after-close release. Day +1 ranges average 6.06%, reflecting substantial intraday swings as the market digests results and guidance.

Investors should prepare for a potentially large move tomorrow. While ResMed has beaten estimates consistently, the stock's reaction has depended heavily on guidance and margin commentary rather than the beat itself—explaining why some beats still triggered selloffs when forward expectations disappointed.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.20% expected move through the August 21 expiration, significantly larger than the 4.87% average historical Day +1 move. This elevated implied volatility suggests options traders are anticipating a more dramatic reaction than typical, possibly reflecting uncertainty around guidance or heightened sensitivity to valuation given the stock's recent run-up.

Part 3: What Analysts Are Saying

Analysts maintain a cautiously optimistic stance on ResMed, with a consensus rating of 3.70 (between Hold and Buy) and an average price target of $238.57—implying approximately 6.5% upside from the current $224.03 price. The rating distribution shows 8 Strong Buys, 0 Moderate Buys, 11 Holds, 0 Moderate Sells, and 1 Strong Sell among 20 analysts covering the stock.

Sentiment has deteriorated over the past month, with the average recommendation slipping from 3.85 to 3.70. This shift reflects one analyst moving from the buy camp to hold, suggesting some concern about valuation or near-term growth sustainability. The number of Hold ratings increased from 9 to 11, while Strong Buys declined from 9 to 8.

The price target range is wide, spanning from a low of $180 to a high of $320, indicating significant disagreement about ResMed's fair value. The mean target of $238.57 sits well below the high-end bull case, suggesting most analysts see modest appreciation potential rather than explosive upside. With the stock currently trading at $224, it sits between the bearish and consensus views, leaving room for either outcome depending on tomorrow's results and guidance.

Part 4: Technical Picture

ResMed's technical setup heading into earnings shows recent strength but longer-term caution. The Barchart Technical Opinion currently registers a 24% Sell signal, unchanged from last week but improved from 40% Sell a month ago, indicating some stabilization in technical momentum after a period of weakness.

Timeframe Analysis:

• Short-term (Hold): Neutral signal suggests near-term momentum has stalled after recent gains, with the stock consolidating ahead of earnings
• Medium-term (50% Sell): Moderate sell signal indicates intermediate-term trend remains under pressure despite recent bounce
• Long-term (50% Sell): Moderate sell signal reflects persistent weakness in the longer-term trend structure

Trend Characteristics: The trend is characterized as Weak and Weakening, suggesting the technical foundation remains fragile heading into this high-stakes earnings event.

The stock is trading at $224.03, positioned above its 5-day ($216.38), 10-day ($209.54), 20-day ($204.34), 50-day ($199.93), and 100-day ($209.38) moving averages, indicating short- to intermediate-term upward momentum. However, the price remains below the critical 200-day moving average at $231.27, a key resistance level that has capped recent rallies and represents a significant technical hurdle.

The moving average structure shows a bullish short-term alignment with all averages through 100 days in upward sequence, but the failure to reclaim the 200-day average suggests the longer-term downtrend remains intact. The stock has rallied approximately 12% from its 50-day low, creating a technically extended position heading into earnings. This setup is double-edged: a strong beat with robust guidance could finally propel RMD above the 200-day resistance and trigger a broader trend reversal, while any disappointment risks a sharp pullback toward the 50-day support near $200. The weak technical opinion ratings across all timeframes suggest the path of least resistance may still be lower absent a significant positive catalyst from tomorrow's report.